BR0312410A - Formulações farmacêuticas de liberação controlada - Google Patents
Formulações farmacêuticas de liberação controladaInfo
- Publication number
- BR0312410A BR0312410A BR0312410-0A BR0312410A BR0312410A BR 0312410 A BR0312410 A BR 0312410A BR 0312410 A BR0312410 A BR 0312410A BR 0312410 A BR0312410 A BR 0312410A
- Authority
- BR
- Brazil
- Prior art keywords
- controlled release
- core
- methyl
- pharmaceutical formulations
- pharmaceutically acceptable
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 4
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 abstract 3
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- -1 benzo [1,3] dioxol-5-yloxy Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"FORMULAçõES FARMACêUTICAS DE LIBERAçãO CONTROLADA". A presente invenção refere-se a formulações farmacêuticas de liberação controlada tendo um núcleo revestido com o núcleo compreendendo uma composição contendo droga e uma composição inchável em água, cada uma ocupando regiões essencialmente separadas dentro do núcleo. A composição contendo droga compreende um inibidor de PDE4D, ou um seu sal farmaceuticamente aceitável, de preferência ácido (R)-2-[4-({[2(benzo[1,3]dioxol-5-ilóxi)-piridina-3-carbonil]-amino}-metil) -3-flúor-fenóxi]-propiónico, ou um seu sal farmaceuticamente aceitável, ou 2-(4-fluor-ofenóxi)-N[4-(1-hidróxi-1-metil-etil)-benzil]-nicotinamida, ou um seu sal farmaceuticamente aceitável, e um agente de aprisionamento de droga. O revestimento em torno do núcleo é permeável à água, insolúvel em água, e tem pelo menos uma porta de aplicação nele. A invenção refere-se ainda a métodos de redução dos efeitos de náusea e êmese dos inibidores de PDE4D, e formulações de liberação controlada tendo perfis de inibidor de PDE4D aperfeiçoados in vivo e in vitro.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39380102P | 2002-07-03 | 2002-07-03 | |
| PCT/IB2003/002877 WO2004004684A1 (en) | 2002-07-03 | 2003-06-26 | Controlled-release pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0312410A true BR0312410A (pt) | 2005-04-26 |
Family
ID=30115647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0312410-0A BR0312410A (pt) | 2002-07-03 | 2003-06-26 | Formulações farmacêuticas de liberação controlada |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040076668A1 (pt) |
| EP (1) | EP1519711A1 (pt) |
| JP (1) | JP2006502108A (pt) |
| AR (1) | AR040378A1 (pt) |
| AU (1) | AU2003244942A1 (pt) |
| BR (1) | BR0312410A (pt) |
| CA (1) | CA2490978A1 (pt) |
| MX (1) | MXPA05000303A (pt) |
| PA (1) | PA8576801A1 (pt) |
| PE (1) | PE20040091A1 (pt) |
| TW (1) | TW200404580A (pt) |
| UY (1) | UY27880A1 (pt) |
| WO (1) | WO2004004684A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050186276A1 (en) * | 2003-07-17 | 2005-08-25 | Pfizer Inc | Pharmaceutical formulations |
| CA2749933A1 (en) * | 2009-02-04 | 2010-08-12 | Supernus Pharmaceuticals, Inc. | Formulations of desvenlafaxine |
| WO2011039686A1 (en) * | 2009-09-30 | 2011-04-07 | Pfizer Inc. | Latrepirdine oral sustained release dosage forms |
| RU2607595C2 (ru) | 2010-02-03 | 2017-01-10 | Фарма Ту Б Лтд. | Составы разагилина с пролонгированным высвобождением и их применение |
| HK1232218A1 (zh) * | 2014-02-05 | 2018-01-05 | Merck Sharp & Dohme Llc | Cgrp-活性化合物的片剂制剂 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| BR112023001615A2 (pt) | 2020-07-29 | 2023-04-04 | Allergan Pharmaceuticals Int Ltd | Tratamento para enxaqueca |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| JP2024533756A (ja) | 2021-09-27 | 2024-09-12 | アラガン ファーマスーティカルズ インターナショナル リミテッド | アトゲパントを含む片頭痛の併用療法 |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| TW202506117A (zh) | 2023-06-26 | 2025-02-16 | 英商維羅納製藥Ｐｌｃ公司 | 顆粒組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2048224T3 (es) * | 1989-03-31 | 1994-03-16 | Walhalla Kalk Entwicklungs Und | Procedimiento para la separacion de arsenico de aguas residuales. |
| NZ337698A (en) * | 1997-04-04 | 2001-07-27 | Pfizer Prod Inc | Nicotinamide derivatives for selective inhibition of phosphodiesterase type 4 (PDE4) and the production of tumour necrosis factor (TNF) useful for the treatment of respiratory, rheumatoid and allergic diseases |
| GEP20043334B (en) * | 1999-12-23 | 2004-03-10 | Pfizer Prod Inc | Hydrogel-Driven Drug Dosage Form |
-
2003
- 2003-06-25 US US10/608,817 patent/US20040076668A1/en not_active Abandoned
- 2003-06-26 AU AU2003244942A patent/AU2003244942A1/en not_active Abandoned
- 2003-06-26 JP JP2004519090A patent/JP2006502108A/ja not_active Withdrawn
- 2003-06-26 CA CA002490978A patent/CA2490978A1/en not_active Abandoned
- 2003-06-26 WO PCT/IB2003/002877 patent/WO2004004684A1/en not_active Ceased
- 2003-06-26 EP EP03738416A patent/EP1519711A1/en not_active Withdrawn
- 2003-06-26 BR BR0312410-0A patent/BR0312410A/pt not_active IP Right Cessation
- 2003-06-26 MX MXPA05000303A patent/MXPA05000303A/es not_active Application Discontinuation
- 2003-07-02 AR ARP030102402A patent/AR040378A1/es unknown
- 2003-07-02 TW TW092118095A patent/TW200404580A/zh unknown
- 2003-07-02 PE PE2003000670A patent/PE20040091A1/es not_active Application Discontinuation
- 2003-07-03 UY UY27880A patent/UY27880A1/es not_active Application Discontinuation
- 2003-07-03 PA PA20038576801A patent/PA8576801A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200404580A (en) | 2004-04-01 |
| UY27880A1 (es) | 2004-02-27 |
| AR040378A1 (es) | 2005-03-30 |
| JP2006502108A (ja) | 2006-01-19 |
| EP1519711A1 (en) | 2005-04-06 |
| CA2490978A1 (en) | 2004-01-15 |
| MXPA05000303A (es) | 2005-03-31 |
| WO2004004684A1 (en) | 2004-01-15 |
| US20040076668A1 (en) | 2004-04-22 |
| AU2003244942A1 (en) | 2004-01-23 |
| PA8576801A1 (es) | 2005-02-04 |
| PE20040091A1 (es) | 2004-02-17 |
| WO2004004684A8 (en) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312410A (pt) | Formulações farmacêuticas de liberação controlada | |
| ES2295609T3 (es) | Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor. | |
| CA2601289A1 (en) | Once-a-day oxycodone formulations | |
| NO20022014L (no) | En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon | |
| NO2016005I1 (no) | 2-okso-1-pyrrolidinderivater, farmasøytisk preparat og deres anvendelse for fremstilling av et medikament | |
| DK1246622T3 (da) | Nye substituerede benzimidazol dosisformer og metoder til deres anvendelse | |
| NO20060974L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
| NO308507B1 (no) | Anvendelse av pyridoner for fremstilling av et farmasøytisk preparat for reparasjon og forhindring av fibrotiske skader | |
| EP1585423A4 (en) | SYSTEMS AND METHODS FOR HEALTH MONITORING AND TRANSDERMAL MEDICAMENT ISSUE | |
| DE69311395D1 (de) | Sphäroidische Arzneimittelformulierung | |
| FI20012462A7 (fi) | Farmaseuttisia formulaatioita ja menetelmiä käsittäen intranasaalista morfiinia | |
| CN102066402B (zh) | 肽衍生物以及含有肽衍生物的用于促进泪液分泌的组合物 | |
| RU2005135649A (ru) | Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги | |
| BRPI0307319B8 (pt) | forma de dosagem oral para liberação controlada de droga e processo para sua preparação | |
| WO2005065641A3 (en) | Non-disintegrating oral solid composition of high dose of water soluble drugs | |
| EE200200472A (et) | Molsidomiini pikendatud vabanemisega suukaudse manustamisega galeeniline ravimvorm | |
| EP1064967A3 (en) | 5HT1 receptor agonists, caffeine and either a COX-2 inhibitor or NSAID for the treatment of migraine | |
| NO20091111L (no) | Anvendelse av R(+)-alfa-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidin-metanol for behandling av sovnforstyrrelser | |
| BR0008543A (pt) | Agente terapêutico para a claudicação intermitente, e, uso de um derivado de piperidina ou de um sal deste farmaceuticamente aceitável | |
| FR2763950B1 (fr) | 2- {4- [4-(4,5-dichloro-2-methylimidazol-1-yl)butyl] -1- piperazinyl }-5-fluoropyrimidine, sa preparation et son utilisation therapeutique | |
| JP2003514015A5 (pt) | ||
| AR038174A1 (es) | Formas de dosis de benzimidazol sustituido y metodos de uso del mismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 4A., 5A., 6A. E 7A. ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010. |